JP2019504086A5 - - Google Patents

Download PDF

Info

Publication number
JP2019504086A5
JP2019504086A5 JP2018540113A JP2018540113A JP2019504086A5 JP 2019504086 A5 JP2019504086 A5 JP 2019504086A5 JP 2018540113 A JP2018540113 A JP 2018540113A JP 2018540113 A JP2018540113 A JP 2018540113A JP 2019504086 A5 JP2019504086 A5 JP 2019504086A5
Authority
JP
Japan
Prior art keywords
antibody
buffered
formulation
buffer
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540113A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504086A (ja
JP7084308B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016040 external-priority patent/WO2017136433A1/en
Publication of JP2019504086A publication Critical patent/JP2019504086A/ja
Publication of JP2019504086A5 publication Critical patent/JP2019504086A5/ja
Application granted granted Critical
Publication of JP7084308B2 publication Critical patent/JP7084308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540113A 2016-02-03 2017-02-01 抗体安定性を増大させるための緩衝液製剤 Active JP7084308B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290654P 2016-02-03 2016-02-03
US62/290,654 2016-02-03
PCT/US2017/016040 WO2017136433A1 (en) 2016-02-03 2017-02-01 Buffer formulations for enhanced antibody stability

Publications (3)

Publication Number Publication Date
JP2019504086A JP2019504086A (ja) 2019-02-14
JP2019504086A5 true JP2019504086A5 (OSRAM) 2020-03-12
JP7084308B2 JP7084308B2 (ja) 2022-06-14

Family

ID=58046768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018540113A Active JP7084308B2 (ja) 2016-02-03 2017-02-01 抗体安定性を増大させるための緩衝液製剤

Country Status (8)

Country Link
US (1) US11285210B2 (OSRAM)
EP (1) EP3411401A1 (OSRAM)
JP (1) JP7084308B2 (OSRAM)
CN (1) CN109563161A (OSRAM)
AU (1) AU2017213775A1 (OSRAM)
CA (1) CA3013336A1 (OSRAM)
MX (1) MX2018009341A (OSRAM)
WO (1) WO2017136433A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
EP2946766B1 (en) * 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
KR20190024572A (ko) * 2017-08-30 2019-03-08 (주)셀트리온 TNFα 관련 질환을 치료하기 위한 피하 투여 요법
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2019246455A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP3810094A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
AU2020207124A1 (en) * 2019-01-11 2021-07-29 Samsung Bioepis Co., Ltd. Pharmaceutical composition comprising antibody, device comprising same, and use thereof
EP4063506A4 (en) * 2019-09-19 2023-09-06 Innovent Biologics (Suzhou) Co., Ltd. Method for preventing or treating cholesterol-related diseases by using anti-pcsk9 antibody
IL297986A (en) 2020-05-08 2023-01-01 Genmab As Bispecific antibodies against cd3 and cd20
CN114652825A (zh) * 2020-12-22 2022-06-24 百奥泰生物制药股份有限公司 稳定的抗体制剂及其制备方法和应用
GB202115127D0 (en) * 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations
GB202115121D0 (en) * 2021-10-21 2021-12-08 Ucb Biopharma Sprl Formulations

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569525A1 (en) 1991-02-01 1993-11-18 Coulter Corporation METHOD OF PRODUCING F(ab') 2? FRAGMENTS OF IMMUNOGLOBULINS
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
KR100960211B1 (ko) 1998-05-06 2010-05-27 제넨테크, 인크. 이온 교환 크로마토그래피에 의한 단백질 정제 방법
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
TW201705980A (zh) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 用於治療TNFα相關失調症之多重可變劑量療法
WO2006096490A2 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc ANTI-MAdCAM ANTIBODY COMPOSITIONS
KR20150055116A (ko) 2005-05-16 2015-05-20 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 tnf 억제제의 용도
US20110008831A1 (en) 2005-05-26 2011-01-13 Cytos Biotechnology Ag Scalable fermentation process
RS52861B (sr) 2005-06-07 2013-12-31 Esbatech - A Novartis Company Llc Stabilna i rastvorljiva antitela koja inhibiraju tnf (alfa)
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20070796A1 (es) 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
NZ567286A (en) 2005-11-01 2012-03-30 Abbott Biotechnolgy Ltd Methods and compositions for diagnosing ankylosing spondylitis using biomarkers
NZ611859A (en) 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
EP2666478A3 (en) 2006-04-10 2014-10-22 AbbVie Biotechnology Ltd Uses and compositions for treatment of psoriasis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
JP5535623B2 (ja) 2006-06-30 2014-07-02 アッヴィ バイオテクノロジー リミテッド 自動注射装置
JP5437633B2 (ja) 2006-09-11 2014-03-12 株式会社 免疫生物研究所 モノクローナル抗体およびその用途
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
EP2500416A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
EP2684895A1 (en) 2006-10-27 2014-01-15 AbbVie Biotechnology Ltd Crystalline anti-hTNFalpha antibodies
CA2681581A1 (en) 2007-03-30 2008-10-09 Abbott Laboratories Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
TWI601823B (zh) 2007-04-26 2017-10-11 Chugai Pharmaceutical Co Ltd Cell culture methods using media containing high concentrations of amino acids
EP2165194A4 (en) 2007-05-31 2010-09-08 Abbott Lab BIOMARKERS FOR PREDICTING RESPONSABILITY TO TNF ALPHA INHIBITORS IN AUTOIMMUNE DISEASES
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009020654A1 (en) 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
ES2750254T3 (es) 2007-09-27 2020-03-25 Amgen Inc Formulaciones farmacéuticas
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI543768B (zh) 2007-11-30 2016-08-01 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
WO2009073805A2 (en) * 2007-12-04 2009-06-11 Verdezyne, Inc. Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences
SG2013054218A (en) 2008-01-15 2014-10-30 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
ATE460666T1 (de) 2008-01-15 2010-03-15 Univ Utrecht Holding Bv Verfahren zur bestimmung der aminosäurensequenz von peptiden
WO2009091912A2 (en) 2008-01-15 2009-07-23 Abbott Laboratories Improved mammalian expression vectors and uses thereof
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
EP2271671A2 (en) 2008-03-24 2011-01-12 Abbott Biotechnology Ltd. Tnf-alpha inhibitors for treating bone loss
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
CN104974251A (zh) 2008-10-20 2015-10-14 Abbvie公司 在抗体纯化过程中的病毒灭活
CN102257004A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 与il-12结合的抗体及其纯化方法
CN105111309A (zh) 2008-10-20 2015-12-02 Abbvie公司 使用a蛋白亲和层析分离和纯化抗体
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
EP2350649A4 (en) 2008-11-28 2012-11-14 Abbott Lab STABLE ANTIBODY COMPOSITIONS AND METHODS FOR STABILIZING THE SAME
KR20120034593A (ko) 2009-03-09 2012-04-12 유니버시티 오브 조지아 리서치 파운데이션 인코퍼레이티드 위암 진단용 단백질 마커의 동정
WO2010129469A1 (en) 2009-05-04 2010-11-11 Abbott Biotechnology Ltd. Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
ES2527173T3 (es) 2009-06-02 2015-01-21 Regeneron Pharmaceuticals, Inc. Células de fucosilación deficiente
WO2010141855A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20110059079A1 (en) 2009-09-04 2011-03-10 Xoma Technology Ltd. Antibody Coformulations
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2538973A2 (en) 2010-02-26 2013-01-02 Novo Nordisk A/S Stable antibody containing compositions
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
BR112012030530A2 (pt) 2010-05-18 2022-12-20 Abbvie Inc Aparelho e processo para purificação de proteínas
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
RS57543B1 (sr) 2010-06-03 2018-10-31 Abbvie Biotechnology Ltd Primene i kompozicije za lečenje hidradenitis suppurativa (hs)
MX2013003182A (es) 2010-09-20 2013-04-24 Abbvie Inc Purificacion de anticuerpos por cromatografia de lecho movil simulada.
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
JP5919606B2 (ja) 2010-11-11 2016-05-18 アッヴィ バイオテクノロジー リミテッド 改良型高濃度抗tnfアルファ抗体液体製剤
SG191371A1 (en) 2010-12-28 2013-08-30 Chugai Pharmaceutical Co Ltd Animal cell culturing method
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
CA2831572C (en) 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
IL288509B2 (en) 2011-07-01 2023-04-01 Amgen Inc Mammalian cell culture
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
CA2850668A1 (en) 2011-10-04 2013-04-11 Expression Pathology, Inc. Srm/mrm assay for the ephrin type-a receptor 2 protein
IN2014CN03936A (OSRAM) 2011-10-24 2015-09-04 Abbvie Inc
EP2773439A4 (en) 2011-10-31 2015-07-01 Merck Sharp & Dohme CHROMATOGRAPHY METHOD FOR RESOLVING HETEROGENIC ANTIBODY AGGREGATES
WO2013114165A1 (en) 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
WO2013114164A1 (en) 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2863951A1 (en) 2012-06-12 2015-04-29 Boehringer Ingelheim International GmbH Pharmaceutical formulation for a therapeutic antibody
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201501715QA (en) 2012-09-07 2015-05-28 Coherus Biosciences Inc Stable aqueous formulations of adalimumab
JP5874587B2 (ja) 2012-09-10 2016-03-02 株式会社島津製作所 アミノ酸配列解析方法及び装置
NO2760138T3 (OSRAM) 2012-10-01 2018-08-04
JP2015531244A (ja) 2012-10-15 2015-11-02 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company タンパク質を製造するための哺乳動物細胞培養方法
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2938323A2 (en) 2012-12-28 2015-11-04 Abbott Cardiovascular Systems, Inc. Therapeutic compositions comprising antibodies
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014151901A1 (en) 2013-03-14 2014-09-25 Abbvie Inc. Improvement of mammalian cell culture performance through surfactant supplementation of feed media
CA2926384A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
WO2014175164A1 (ja) 2013-04-25 2014-10-30 株式会社カネカ Fab型抗体の分泌量を増大できるFd鎖遺伝子又はL鎖遺伝子
US9416181B2 (en) 2013-05-06 2016-08-16 Abbvie Inc. Compositions for cell culture and methods of using the same
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
WO2015051310A2 (en) 2013-10-03 2015-04-09 Bioanalytix, Inc. Mass spectrometry-based method for identifying and maintaining quality control factors during the development and manufacture of a biologic
WO2015057910A1 (en) 2013-10-16 2015-04-23 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015140700A1 (en) 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
LT2946765T (lt) 2014-05-23 2016-11-25 Ares Trading S.A. Skysta farmacinė kompozicija
HUP1400510A1 (hu) * 2014-10-28 2016-05-30 Richter Gedeon Nyrt Gyógyászati TNFalfa ellenes antitest készítmény
CN105044222B (zh) 2014-12-19 2017-09-12 浙江辉肽生命健康科技有限公司 生物活性多肽的分析测试和鉴定方法
EP3247718B1 (en) 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
UY36542A (es) 2015-01-28 2016-08-31 Mabxience S A Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
CN105779394B (zh) 2015-03-20 2020-03-24 广东东阳光药业有限公司 一种降低抗体酸性峰含量和改良抗体糖型的细胞培养方法
CA3010598A1 (en) 2016-01-06 2017-07-13 Oncobiologics, Inc. Modulation of afucosylated species in a monoclonal antibody composition
US20190048070A1 (en) 2016-01-06 2019-02-14 Oncobiologics, Inc. Reduction of high molecular weight species, acidic charge species and fragments in a monoclonal antibody composition
WO2017136433A1 (en) 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
JP7224914B2 (ja) 2016-02-04 2023-02-20 アウトルック セラピューティクス,インコーポレイティド タンパク質のアミノ酸配列の同定及び分析方法

Similar Documents

Publication Publication Date Title
JP2019504086A5 (OSRAM)
JP2020518599A5 (OSRAM)
JP2015510882A5 (OSRAM)
JP2015527402A5 (OSRAM)
JP2013543505A5 (OSRAM)
JP2020138981A5 (OSRAM)
JP2015231997A5 (OSRAM)
JP2015508774A5 (OSRAM)
JP2019536761A5 (OSRAM)
JP2013531679A5 (OSRAM)
PE20050586A1 (es) Preparacion farmaceutica que comprende un anticuerpo contra el receptor egfr
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
JP2018510132A5 (OSRAM)
JP2016515515A5 (OSRAM)
JP2013545745A5 (OSRAM)
HRP20201268T1 (hr) Stabilne formulacije koje sadrže anti-pcsk9 antitijela
JP2012526121A5 (OSRAM)
RU2011127913A (ru) Составы, содержащие антитела
JP2015526440A5 (OSRAM)
HRP20191199T1 (hr) Formulacije protutijela anti-prolaktinskog receptora
HRP20241526T1 (hr) Stabilni višedozni pripravci, koji sadrže protutijelo i konzervans
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
ATE522225T1 (de) Verwendung des peptids phpfhlfvy (renin- inhibitor) in anti-angiogenischer therapie von gewissen erkrankungen
JP2017516848A5 (OSRAM)
JP2015535237A5 (OSRAM)